RSS-Feed abonnieren
![](/products/assets/desktop/img/oa-logo.png)
DOI: 10.1055/a-0715-2964
Interdisciplinary Diagnosis, Therapy and Follow-up of Patients with Endometrial Cancer. Guideline (S3-Level, AWMF Registry Number 032/034-OL, April 2018) – Part 2 with Recommendations on the Therapy and Follow-up of Endometrial Cancer, Palliative Care, Psycho-oncological/Psychosocial Care/Rehabilitation/Patient Information and Healthcare Facilities
Artikel in mehreren Sprachen: English | deutschPublikationsverlauf
received 21. August 2018
revised 23. August 2018
accepted 23. August 2018
Publikationsdatum:
26. November 2018 (online)
![](https://www.thieme-connect.de/media/gebfra/201811/lookinside/thumbnails/10-1055-a-0715-2964_gf7152964_en-1.jpg)
Abstract
Summary The first German interdisciplinary S3-guideline on the diagnosis, therapy and follow-up of patients with endometrial cancer was published in April 2018. Funded by German Cancer Aid as part of an Oncology Guidelines Program, the lead coordinators of the guideline were the German Society of Gynecology and Obstetrics (DGGG) and the Gynecological Oncology Working Group (AGO) of the German Cancer Society (DKG).
Purpose Using evidence-based, risk-adapted therapy to treat low-risk women with endometrial cancer avoids unnecessarily radical surgery and non-useful adjuvant radiotherapy and/or chemotherapy. This can significantly reduce therapy-induced morbidity and improve the patientʼs quality of life as well as avoiding unnecessary costs. For women with endometrial cancer and a high risk of recurrence, the guideline defines the optimal extent of surgical radicality together with the appropriate chemotherapy and/or adjuvant radiotherapy if required. An evidence-based optimal use of different therapeutic modalities should improve the survival rates and quality of life of these patients. This S3-guideline on endometrial cancer is intended as a basis for certified gynecological cancer centers. The aim is that the quality indicators established in this guideline will be incorporated in the certification processes of these centers.
Methods The guideline was compiled in accordance with the requirements for S3-level guidelines. This includes, in the first instance, the adaptation of source guidelines selected using the DELBI instrument for appraising guidelines. Other consulted sources included reviews of evidence, which were compiled from literature selected during systematic searches of literature databases using the PICO scheme. In addition, an external biostatistics institute was commissioned to carry out a systematic search and assessment of the literature for one part of the guideline. Identified materials were used by the interdisciplinary working groups to develop suggestions for Recommendations and Statements, which were then subsequently modified during structured consensus conferences and/or additionally amended online using the DELPHI method, with consent between members achieved online. The guideline report is freely available online.
Recommendations Part 2 of this short version of the guideline presents recommendations for the therapy of endometrial cancer including precancers and early endometrial cancer as well as recommendations on palliative medicine, psycho-oncology, rehabilitation, patient information and healthcare facilities to treat endometrial cancer. The management of precancers of early endometrial precancerous conditions including fertility-preserving strategies is presented. The concept used for surgical primary therapy of endometrial cancer is described. Radiotherapy and adjuvant medical therapy to treat endometrial cancer and uterine carcinosarcomas are described. Recommendations are given for the follow-up care of endometrial cancer, recurrence and metastasis. Palliative medicine, psycho-oncology including psychosocial care, and patient information and rehabilitation are presented. Finally, the care algorithm and quality assurance steps for the diagnosis, therapy and follow-up of patients with endometrial cancer are outlined.
-
References/Literatur
- 1 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). Diagnostik, Therapie und Nachsorge der Patientinnen mit Endometriumkarzinom Leitlinienreport 1.0, 2018, AWMF Registernummer: 032/034-OL. 2018. Online: https://www.leitlinienprogramm-onkologie.de/leitlinien/endometriumkarzinom/ last access: 13.08.2018
- 2 Atkins D, Best D, Briss PA. et al. Grading quality of evidence and strength of recommendations. BMJ 2004; 328: 1490
- 3 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Ständige Kommission Leitlinien. AWMF-Regelwerk „Leitlinien“. 2012. Online: https://www.awmf.org/leitlinien/awmf-regelwerk.html last access: 13.08.2018
- 4 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. (AWMF), Ärztliches Zentrum für Qualität in der Medizin (ÄZQ), Gemeinsame Einrichtung von Bundesärztekammer und Kassenärztlicher Bundesvereinigung. Deutsches Instrument zur methodischen Leitlinien-Bewertung (DELBI). Fassung 2005/2006 + Domäne 8 (2008). Online: https://www.leitlinien.de/mdb/edocs/pdf/literatur/delbi-fassung-2005-2006-domaene-8-2008.pdf last access: 13.08.2018
- 5 Zaino R, Carinelli SG, Ellenson LH. Tumours of the uterine Corpus: epithelial Tumours and Precursors. In: Kurman RJ CM, Herrington CS, Young RH. eds. WHO Classification of Tumours of female reproductive Tract. Lyon: IARC Press; 2014: 125-126
- 6 Antonsen SL, Ulrich L, Hogdall C. Patients with atypical hyperplasia of the endometrium should be treated in oncological centers. Gynecol Oncol 2012; 125: 124-128
- 7 Gunderson CC, Fader AN, Carson KA. et al. Oncologic and reproductive outcomes with progestin therapy in women with endometrial hyperplasia and grade 1 adenocarcinoma: a systematic review. Gynecol Oncol 2012; 125: 477-482
- 8 Luo L, Luo B, Zheng Y. et al. Levonorgestrel-releasing intrauterine system for atypical endometrial hyperplasia. Cochrane Database Syst Rev 2013; (06) CD009458
- 9 Gallos ID, Yap J, Rajkhowa M. et al. Regression, relapse, and live birth rates with fertility-sparing therapy for endometrial cancer and atypical complex endometrial hyperplasia: a systematic review and metaanalysis. Am J Obstet Gynecol 2012; 207: 266.e1-266.e12
- 10 Baker J, Obermair A, Gebski V. et al. Efficacy of oral or intrauterine device-delivered progestin in patients with complex endometrial hyperplasia with atypia or early endometrial adenocarcinoma: a meta-analysis and systematic review of the literature. Gynecol Oncol 2012; 125: 263-270
- 11 Koskas M, Uzan J, Luton D. et al. Prognostic factors of oncologic and reproductive outcomes in fertility-sparing management of endometrial atypical hyperplasia and adenocarcinoma: systematic review and meta-analysis. Fertil Steril 2014; 101: 785-794
- 12 Chan JK, Wu H, Cheung MK. et al. The outcomes of 27,063 women with unstaged endometrioid uterine cancer. Gynecol Oncol 2007; 106: 282-288
- 13 Takano M, Ochi H, Takei Y. et al. Surgery for endometrial cancers with suspected cervical involvement: is radical hysterectomy needed (a GOTIC study)?. Br J Cancer 2013; 109: 1760-1765
- 14 Frost JA, Webster KE, Bryant A. et al. Lymphadenectomy for the management of endometrial cancer. Cochrane Database Syst Rev 2015; (09) CD007585
- 15 Todo Y, Kato H, Kaneuchi M. et al. Survival effect of para-aortic lymphadenectomy in endometrial cancer (SEPAL study): a retrospective cohort analysis. Lancet 2010; 375: 1165-1172
- 16 Kim HS, Suh DH, Kim MK. et al. Systematic lymphadenectomy for survival in patients with endometrial cancer: a meta-analysis. Jpn J Clin Oncol 2012; 42: 405-412
- 17 Nemani D, Mitra N, Guo M. et al. Assessing the effects of lymphadenectomy and radiation therapy in patients with uterine carcinosarcoma: a SEER analysis. Gynecol Oncol 2008; 111: 82-88
- 18 Odagiri T, Watari H, Kato T. et al. Distribution of lymph node metastasis sites in endometrial cancer undergoing systematic pelvic and para-aortic lymphadenectomy: a proposal of optimal lymphadenectomy for future clinical trials. Ann Surg Oncol 2014; 21: 2755-2761
- 19 Alay I, Turan T, Ureyen I. et al. Lymphadenectomy should be performed up to the renal vein in patients with intermediate-high risk endometrial cancer. Pathol Oncol Res 2015; 21: 803-810
- 20 Galaal K, Bryant A, Fisher AD. et al. Laparoscopy versus laparotomy for the management of early stage endometrial cancer. Cochrane Database Syst Rev 2012; (09) CD006655
- 21 Tanner EJ, Leitao jr. MM, Garg K. et al. The role of cytoreductive surgery for newly diagnosed advanced-stage uterine carcinosarcoma. Gynecol Oncol 2011; 123: 548-552
- 22 Barlin JN, Puri I, Bristow RE. Cytoreductive surgery for advanced or recurrent endometrial cancer: a meta-analysis. Gynecol Oncol 2010; 118: 14-18
- 23 Klopp A, Smith BD, Alektiar K. et al. The role of postoperative radiation therapy for endometrial cancer: Executive summary of an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol 2014; 4: 137-144
- 24 Kong A, Johnson N, Kitchener HC. et al. Adjuvant radiotherapy for stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis. J Natl Cancer Inst 2012; 104: 1625-1634
- 25 Sorbe B, Nordstrom B, Maenpaa J. et al. Intravaginal brachytherapy in FIGO stage I low-risk endometrial cancer: a controlled randomized study. Int J Gynecol Cancer 2009; 19: 873-878
- 26 Ortoft G, Hansen ES, Bertelsen K. Omitting adjuvant radiotherapy in endometrial cancer increases the rate of locoregional recurrences but has no effect on long-term survival: the Danish Endometrial Cancer Study. Int J Gynecol Cancer 2013; 23: 1429-1437
- 27 Nout RA, Putter H, Jurgenliemk-Schulz IM. et al. Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. J Clin Oncol 2009; 27: 3547-3556
- 28 Nout RA, Smit VT, Putter H. et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 2010; 375: 816-823
- 29 Nout RA, van de Poll-Franse LV, Lybeert ML. et al. Long-term outcome and quality of life of patients with endometrial carcinoma treated with or without pelvic radiotherapy in the post operative radiation therapy in endometrial carcinoma 1 (PORTEC-1) trial. J Clin Oncol 2011; 29: 1692-1700
- 30 van der Steen-Banasik E, Christiaens M, Shash E. et al. Systemic review: Radiation therapy alone in medical non-operable endometrial carcinoma. Eur J Cancer 2016; 65: 172-181
- 31 Reed NS, Mangioni C, Malmstrom H. et al. Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer 2008; 44: 808-818
- 32 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). Diagnostik, Therapie und Nachsorge der Patientinnen mit Endometriumkarzinom, Langversion 1.0, 2018, AWMF Registernummer: 032/034-OL. 2018. Online: https://www.leitlinienprogramm-onkologie.de/leitlinien/endometriumkarzinom/ last access: 13.08.2018
- 33 Martin-Hirsch PPL, Bryant A, Keep SL. et al. Adjuvant progestagens for endometrial cancer. Cochrane Database Syst Rev 2011; (06) CD001040
- 34 Johnson N, Bryant A, Miles T. et al. Adjuvant chemotherapy for endometrial cancer after hysterectomy. Cochrane Database Syst Rev 2011; (10) CD003175
- 35 Galaal K, Al Moundhri M, Bryant A. et al. Adjuvant chemotherapy for advanced endometrial cancer. Cochrane Database Syst Rev 2014; (05) CD010681
- 36 Cantrell LA, Havrilesky L, Moore DT. et al. A multi-institutional cohort study of adjuvant therapy in stage I–II uterine carcinosarcoma. Gynecol Oncol 2012; 127: 22-26
- 37 Galaal K, van der Heijden E, Godfrey K. et al. Adjuvant radiotherapy and/or chemotherapy after surgery for uterine carcinosarcoma. Cochrane Database Syst Rev 2013; (02) CD006812
- 38 Sutton G, Brunetto VL, Kilgore L. et al. A phase III trial of ifosfamide with or without cisplatin in carcinosarcoma of the uterus: A Gynecologic Oncology Group Study. Gynecol Oncol 2000; 79: 147-153
- 39 Homesley HD, Filiaci V, Markman M. et al. Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study. J Clin Oncol 2007; 25: 526-531
- 40 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). S3-Leitlinie Supportive Therapie bei onkologischen Patientinnen, Langversion 1.1 – April 2017, AWMF-Registernummer: 032/054OL. 2017. Online: https://www.leitlinienprogramm-onkologie.de/leitlinien/supportive-therapie/ last access: 13.08.2018
- 41 IKNL, IKN. Endometriumcarcinoom. Versie: 3.0, 24.10.2011. Landelijke richtlijn. Oncoline; 2011. Online: https://oncoline.nl/endometriumcarcinoom last access: 13.08.2018
- 42 Fung-Kee-Fung M, Dodge J, Elit L. et al. Follow-up after primary therapy for endometrial cancer: a systematic review. Gynecol Oncol 2006; 101: 520-529
- 43 Gadducci A, Cosio S, Fanucchi A. et al. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer. Anticancer Res 2000; 20: 1977-1984
- 44 Sartori E, Pasinetti B, Carrara L. et al. Pattern of failure and value of follow-up procedures in endometrial and cervical cancer patients. Gynecol Oncol 2007; 107: S241-S247
- 45 Smith CJ, Heeren M, Nicklin JL. et al. Efficacy of routine follow-up in patients with recurrent uterine cancer. Gynecol Oncol 2007; 107: 124-129
- 46 Carrara L, Gadducci A, Landoni F. et al. Could different follow-up modalities play a role in the diagnosis of asymptomatic endometrial cancer relapses?: an Italian multicentric retrospective analysis. Int J Gynecol Cancer 2012; 22: 1013-1019
- 47 Creutzberg CL, van Putten WL, Koper PC. et al. Survival after relapse in patients with endometrial cancer: results from a randomized trial. Gynecol Oncol 2003; 89: 201-209
- 48 Reddoch JM, Burke TW, Morris M. et al. Surveillance for recurrent endometrial carcinoma: development of a follow-up scheme. Gynecol Oncol 1995; 59: 221-225
- 49 Bristow RE, Purinton SC, Santillan A. et al. Cost-effectiveness of routine vaginal cytology for endometrial cancer surveillance. Gynecol Oncol 2006; 103: 709-713
- 50 Salani R, Nagel CI, Drennen E. et al. Recurrence patterns and surveillance for patients with early stage endometrial cancer. Gynecol Oncol 2011; 123: 205-207
- 51 Lalwani N, Dubinsky T, Javitt MC. et al. ACR Appropriateness Criteria(®) pretreatment evaluation and follow-up of endometrial cancer. Ultrasound Q 2014; 30: 21-28
- 52 Kadkhodayan S, Shahriari S, Treglia G. et al. Accuracy of 18-F-FDG PET imaging in the follow up of endometrial cancer patients: systematic review and meta-analysis of the literature. Gynecol Oncol 2013; 128: 397-404
- 53 Kokka F, Brockbank E, Oram D. et al. Hormonal therapy in advanced or recurrent endometrial cancer. Cochrane Database Syst Rev 2010; (12) CD007926
- 54 Thigpen JT, Brady MF, Alvarez RD. et al. Oral medroxyprogesterone acetate in the treatment of advanced or recurrent endometrial carcinoma: a dose-response study by the Gynecologic Oncology Group. J Clin Oncol 1999; 17: 1736-1744
- 55 Covens AL, Filiaci V, Gersell D. et al. Phase II study of fulvestrant in recurrent/metastatic endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2011; 120: 185-188
- 56 Vale CL, Tierney J, Bull SJ. et al. Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. Cochrane Database Syst Rev 2012; (08) CD003915
- 57 Lee YK, Chung HH, Kim JW. et al. Vaginal pH-balanced gel for the control of atrophic vaginitis among breast cancer survivors: a randomized controlled trial. Obstet Gynecol 2011; 117: 922-927
- 58 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). Palliativmedizin für Patienten mit einer nicht heilbaren Krebserkrankung, Langversion 1.0, 2015, AWMF-Registernummer: 128/001OL. 2015. Online: https://www.leitlinienprogramm-onkologie.de/leitlinien/palliativmedizin/ last access: 13.08.2018
- 59 Temel JS, Greer JA, Muzikansky A. et al. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010; 363: 733-742
- 60 Brumley R, Enguidanos S, Jamison P. et al. Increased satisfaction with care and lower costs: results of a randomized trial of in-home palliative care. J Am Geriatr Soc 2007; 55: 993-1000
- 61 Pantilat SZ, OʼRiordan DL, Dibble SL. et al. Hospital-based palliative medicine consultation: a randomized controlled trial. Arch Intern Med 2010; 170: 2038-2040
- 62 Bakitas MA, Tosteson TD, Li Z. et al. Early Versus Delayed Initiation of Concurrent Palliative Oncology Care: Patient Outcomes in the ENABLE III Randomized Controlled Trial. J Clin Oncol 2015; 33: 1438-1445
- 63 Zimmermann C, Swami N, Krzyzanowska M. et al. Early palliative care for patients with advanced cancer: a cluster-randomised controlled trial. Lancet 2014; 383: 1721-1730
- 64 Rugno FC, Paiva BS, Paiva CE. Early integration of palliative care facilitates the discontinuation of anticancer treatment in women with advanced breast or gynecologic cancers. Gynecol Oncol 2014; 135: 249-254
- 65 Maltoni M, Scarpi E, DallʼAgata M. et al. Systematic versus on-demand early palliative care: results from a multicentre, randomised clinical trial. Eur J Cancer 2016; 65: 61-68
- 66 Temel JS, Greer JA, El-Jawahri A. et al. Effects of Early Integrated Palliative Care in Patients With Lung and GI Cancer: A Randomized Clinical Trial. J Clin Oncol 2017; 35: 834-841
- 67 Kavalieratos D, Corbelli J, Zhang D. et al. Association Between Palliative Care and Patient and Caregiver Outcomes: A Systematic Review and Meta-analysis. JAMA 2016; 316: 2104-2114
- 68 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF). S3-Leitlinie Diagnostik, Therapie und Nachsorge der Patientin mit Zervixkarzinom, Version 1.0, September 2014, AWMF-Registernummer: 032/033OL. 2014. Online: https://www.leitlinienprogramm-onkologie.de/leitlinien/zervixkarzinom/ last access: 13.08.2018
- 69 Arbeitsgemeinschaft für Urogynäkologie und Plastische Beckenbodenrekonstruktion, AWMF. Interdisziplinäre S2e-Leitlinie für die Diagnostik und Therapie der Belastungsinkontinenz der Frau, AWMF-Registernummer: 015/005. 2013;. Online: http://www.awmf.org/leitlinien/detail/ll/015-005.html last access: 13.08.2018
- 70 Adamsen L, Quist M, Andersen C. et al. Effect of a multimodal high intensity exercise intervention in cancer patients undergoing chemotherapy: randomised controlled trial. BMJ 2009; 339: b3410
- 71 Bourke L, Thompson G, Gibson DJ. et al. Pragmatic lifestyle intervention in patients recovering from colon cancer: a randomized controlled pilot study. Arch Phys Med Rehabil 2011; 92: 749-755
- 72 Brown JC, Huedo-Medina TB, Pescatello LS. et al. Efficacy of exercise interventions in modulating cancer-related fatigue among adult cancer survivors: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2011; 20: 123-133
- 73 Cantarero-Villanueva I, Fernandez-Lao C, Del Moral-Avila R. et al. Effectiveness of core stability exercises and recovery myofascial release massage on fatigue in breast cancer survivors: a randomized controlled clinical trial. Evid Based Complement Alternat Med 2012; 2012: 620619
- 74 Chandwani KD, Thornton B, Perkins GH. et al. Yoga improves quality of life and benefit finding in women undergoing radiotherapy for breast cancer. J Soc Integr Oncol 2010; 8: 43-55
- 75 Courneya KS, Segal RJ, Reid RD. et al. Three independent factors predicted adherence in a randomized controlled trial of resistance exercise training among prostate cancer survivors. J Clin Epidemiol 2004; 57: 571-579
- 76 Cramp F, Byron-Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev 2012; (11) CD006145
- 77 Danhauer SC, Mihalko SL, Russell GB. et al. Restorative yoga for women with breast cancer: findings from a randomized pilot study. Psychooncology 2009; 18: 360-368
- 78 Donnelly CM, Blaney JM, Lowe-Strong A. et al. A randomised controlled trial testing the feasibility and efficacy of a physical activity behavioural change intervention in managing fatigue with gynaecological cancer survivors. Gynecol Oncol 2011; 122: 618-624
- 79 Fillion L, Gagnon P, Leblond F. et al. A brief intervention for fatigue management in breast cancer survivors. Cancer Nurs 2008; 31: 145-159
- 80 Heim ME, von der Malsburg ML, Niklas A. Randomized controlled trial of a structured training program in breast cancer patients with tumor-related chronic fatigue. Onkologie 2007; 30: 429-434
- 81 Littman AJ, Bertram LC, Ceballos R. et al. Randomized controlled pilot trial of yoga in overweight and obese breast cancer survivors: effects on quality of life and anthropometric measures. Support Care Cancer 2012; 20: 267-277
- 82 Moadel AB, Shah C, Wylie-Rosett J. et al. Randomized controlled trial of yoga among a multiethnic sample of breast cancer patients: effects on quality of life. J Clin Oncol 2007; 25: 4387-4395
- 83 Mustian KM, Peppone L, Darling TV. et al. A 4-week home-based aerobic and resistance exercise program during radiation therapy: a pilot randomized clinical trial. J Support Oncol 2009; 7: 158-167
- 84 Pinto BM, Rabin C, Papandonatos GD. et al. Maintenance of effects of a home-based physical activity program among breast cancer survivors. Support Care Cancer 2008; 16: 1279-1289
- 85 Rogers LQ, Hopkins-Price P, Vicari S. et al. Physical activity and health outcomes three months after completing a physical activity behavior change intervention: persistent and delayed effects. Cancer Epidemiol Biomarkers Prev 2009; 18: 1410-1418
- 86 Velthuis MJ, Agasi-Idenburg SC, Aufdemkampe G. et al. The effect of physical exercise on cancer-related fatigue during cancer treatment: a meta-analysis of randomised controlled trials. Clin Oncol (R Coll Radiol) 2010; 22: 208-221
- 87 van Weert E, May AM, Korstjens I. et al. Cancer-related fatigue and rehabilitation: a randomized controlled multicenter trial comparing physical training combined with cognitive-behavioral therapy with physical training only and with no intervention. Phys Ther 2010; 90: 1413-1425